1446090-79-4

Usage

Uses

Used in Pharmaceutical Industry:
5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one is used as a pharmaceutical compound for its potential therapeutic applications. The compound's unique structure may allow it to interact with specific biological targets, making it a candidate for the development of new drugs.
Used in Anticancer Applications:
In the field of oncology, 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one may be used as an anticancer agent, targeting various types of cancer cells. Its specific molecular structure could enable it to modulate oncological signaling pathways, inhibit tumor growth, and enhance the efficacy of conventional chemotherapeutic drugs.
Used in Drug Delivery Systems:
To improve the bioavailability and therapeutic outcomes of 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one, novel drug delivery systems can be developed. These systems may involve the use of organic and metallic nanoparticles as carriers, facilitating the compound's delivery to target cells and enhancing its overall effectiveness.
Used in Combination Treatments:
Similar to lifirafenib, a quinoline derivative used for the combination treatment of small cell lung cancer, 5-((1-(6-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-5-yl)oxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one may also be utilized in combination therapies. This approach could potentially enhance the treatment's effectiveness and overcome resistance issues in various types of cancer.

Upstream product

• 13391-28-1 5-methoxybenzofuran 
• 1446091-46-8 (1S,1aS,6bR)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid 
• 1446091-45-7 (1S,1aS,6bR)-5-((7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy)-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid ethyl ester 
• 1446091-43-5 (1S,1aS,6bR)-5-hydroxy-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid ethyl ester 
• 1446091-44-6 (1S,1aS,6bR)-5-((tert-butyldimethylsilyl)oxy)-1a,6b-dihydro-1H-cyclopropane[b]benzofuran-1-carboxylic acid ethyl ester 
• 368-71-8 4-(trifluoromethyl)-1,2-phenylenediamine 
• 13196-10-6 benzofuran-5-ol 
• 1237535-78-2 5-fluoro-3,4-dihydro-1,8-naphthyridine-2(1H)-one 

Relevant academic research and scientific papers

COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER

Disclosed herein is a pharmaceutical combination for use in the prevention, delay of progression or treatment of cancer, wherein the pharmaceutical combination exhibits a synergistic efficacy. The pharmaceutical combination comprises a humanized antagonist monoclonal antibody against PD- and a RAF inhibitor. Also disclosed herein is a combination for use in the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject a therapeutically effective amount of a humanized antagonist monoclonal antibody against PD-1 and a therapeutically effective amount of a RAF inhibitor.

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

MALEATE SALTS OF A B-RAF KINASE INHIBITOR, CRYSTALLINE FORMS, METHODS OF PREPARATION, AND USES THEREFORE

The invention relates to 5- ( ( (1R, 1aS, 6bR) -1- (6- (trifluoromethyl) -1H-benzo [d] imidazol-2-yl) -1a,6b-dihydro-1H-cyclopropa [b] benzofuran-5-yl) oxy) -3, 4-dihydro-1, 8-naphthyridin-2 (1H) -one (Compound 1) maleate salts, in particular the sesqui-maleate salt and its crystalline forms, methods of preparation, pharmaceutical compositions, and therapeutic uses for treatment of diseases or disorders mediated by BRAF or other kinases.

Condensed tricyclic compounds as RAF kinase inhibitors

The invention provides certain condensed tricyclic compounds as well as salt, compositions and application methods thereof.

CONDENSED TRICYCLIC COMPOUNDS AS Raf KINASE INHIBITORS

PROBLEM TO BE SOLVED: To provide specific tricyclic compounds that can be useful for inhibiting Raf kinase and for treating disorders mediated by Raf kinase. SOLUTION: A compound is represented by the general formula 1 in the figure. (Q is C or N; W is C or N; X is CH2 or O; Y is NR12, O or S; Z is O, S, NR13, CO, SO, SO2 or CR13R14; R1 to R6 are each independently hydrogen, halogen, haloalkyl, alkyl or the like.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPO&INPIT

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.

FUSED TRICYCLIC COMPOUNDS AS RAF KINASE INHIBITORS

Provided are certain fused tricyclic compounds and salts thereof, compositions thereof, and methods of use therefor.